B. Riley views Fusion Pharmaceuticals’ license agreement with Heidelberg University for FPI-2265 to settle the inter partes review as “hugely positive.” The news could convince more investors to step away from the sideline, the analyst tells investors in a research note. The firm reiterates a Buy rating on Fusion with a $13 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FUSN:
- Fusion Pharmaceuticals Expands Cancer Treatment Rights and Settles Review
- Fusion Pharmaceuticals enters license agreement with Heidelberg Univ., Euratom
- Leerink MedaCorp specialist holds an analyst/industry conference call
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Fusion Pharmaceuticals price target raised to $16 from $15 at Raymond James